Xact Bio, Inc. — SEC Form D Filing

Xact Bio, Inc. filed an SEC Form D on September 28, 2026, reporting $10.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 28, 2026
Amount reported
$10.00M
Round stage
Series A, given that a $10M equity round aligns with standard early-stage biotechnology financing for preclinical development.
Industry
Biotechnology
Website
https://www.xactbio.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional biological therapies often lack the cellular precision required to deliver therapeutic payloads without triggering severe off-target toxicity.

Solution

Xact Bio develops a precision biotechnology platform engineered to create highly specific biological therapeutics for targeted disease intervention.

Why now

Recent breakthroughs in synthetic biology and computational protein design allow for unprecedented accuracy in targeting complex disease mechanisms.

Verdict

Investors backed this pre-seed round anticipating a high-impact platform technology that could open significant markets for RNA therapeutics beyond liver targets. This cleared because the ambition to unlock a broad therapeutic modality for extra-hepatic applications offered a substantial optionality premium, not because the specific target indications or clinical pathways were well-defined. The implicit bet was on the scientific breakthrough of a generalized delivery mechanism, rather than a de-risked specific asset. Upside was limited by the significant technical and regulatory hurdles inherent in novel systemic delivery, which often results in platform plays being acquired for their technical capability rather than independently scaling clinical operations.

Source: SEC EDGAR Form D filing